SUMMARY Longitudinal height data and physical development were assessed in 29 boys and 12 girls taking long term steroid treatment for steroid sensitive nephrotic syndrome. Growth in both boys and girls, assessed by changes in height standard deviation score (AHt SDS), worsened significantly with chronological age. There was a significant negative correlation between AHt SDS and duration of treatment in boys, but not in girls. There was no correlation between AHt SDS and relapse rate or the use of cyclophosphamide. In the boys, Ht SDS decreased significantly only after the age of 10 years and was associated with delay in the appearance of secondary sexual characteristics.
The adverse effects of steroid treatment on growth have been related to both dosage and duration of treatment.' 1 Many children with steroid sensitive nephrotic syndrome receive steroid treatment for several years and in many cases treatment continues throughout adolescence.4 Current practice for long term treatment is to use a single dose of prednisolone on alternate mornings. This regimen has been suggested to minimise growth retardation and to leave final height unaffected`7; 'catch-up' growth has been reported after treatment is stopped.8
We have observed, however, several adolescents taking long term alternate day steroids for steroid sensitive nephrotic syndrome who were significantly short or whose sexual maturation was delayed,or both, and who, as a result, were severely emotionally disturbed. Retrospective analysis of the longitudinal growth patterns of subjects currently attending our paediatric renal clinic with this syndrome, suggested that after the age of 10 years maturational delay was a prominent clinical feature. We therefore investigated the endocrine function of boys with steroid sensitive nephrotic syndrome in an attempt to determine the site of action of steroids on the hypothalamic-pituitary-gonadal axis, which may account for delayed puberty and subsequent short stature.
Patients and methods
All the subjects with steroid sensitive nephrotic syndrome who were steroid dependent and attended Guy's Hospital paediatric renal clinic between July 1984 and January 1986 were included in the study (total 41: 29 boys, 12 girls). Relapses of proteinuria were treated with prednisolone (60 mg/m2/day) and maintenance steroids were given on alternate days at the dose found to be necessary to keep the urine protein free. An eight week course of cyclophosphamide (2-5-3 mg/kg/day) was given to children who required unacceptably high doses of maintenance steroids to prevent relapse. All subjects had normal plasma creatinine concentrations.
The following were obtained from the notes and at examination:
( (nmolIl) and insulin like growth factor I (IGF-1, U/ml) in intermittent samples throughout the night. All samples from each profile were batch analysed.
Growth hormone was measured by radioimmunoassay using the first International Reference Preparation (IRP) reference 66/217, with intra-assay coefficient of variation of 5-0% and 2-4% at 10-8 and 20-4 mU/l respectively and interassay coefficient of variation of 10*1% at 7-5 mU/1. Gonadotrophins were measured by radioimmunoassay using the first IRP reference of luteinising hormone, 68/40 and follicle stimulating hormone, 78/549, with an intraassay coefficient of variation of (a) luteinising hormone, 8-3% and 10% at 2-4 and 15-0 IU/l, respectively and (b) follicle stimulating hormone, 10-3% and 7-3% at 2-8 and 14-9 IU/l; testosterone was measured by radioimmunoassay using a standard kit method (Diagnostic Products Corporation). Serum IGF-1 was measured by radioimmunoassay after acid-ethanol extraction.12 Antiserum R557A and t25 I-IGF-1 3 were kindly provided by Dr D J Morrell (Institute of Child Health, London). Intra-assay and interassay coefficients of variation were <8% and <10% respectively. IGF-1 values are expressed as potency relative to pooled normal adult human reference serum defined as 1 unit IGF-1/ml. Growth hormone and gonadotrophin hormone peak analysis was performed both visually and using the 'Pulsar' programme14 which was modified locally to include a calculation of area under the curve by summation of trapezoids. Statistical comparison of the association of overnight profile measurements Table 1 Median (range) age at diagnosis and at first and last examination and duration of treatment There was a significant negative correlation between AHt SDS and age at final examination (boys, r=-050, p<0-01, girls r=-0-61, p<0-05); (fig 1) .
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There was also a significant negative correlation between AHt SDS and duration of treatment (fig 2) for the boys (r=-0.64, p<0-01) but not the girls (r=-0.24, p=05). Only three girls, however, had been treated for more than five years.
To attempt to clarify the relative effects of age and duration of treatment we examined the data longitudinally. The AHt SDS from first height at roughly yearly intervals is shown in fig 3. The mean fall in Ht SDS after the age of 10 years until final examination was significantly greater than the fall in Ht SDS from first height measurement until the age of 10 years for the boys (F= 10-25, p<0-01), but the difference was not significant for the girls (F=4-06, p<0-1). Only five boys developed steroid sensitive nephrotic syndrome over the age of 8 years (mean 11-0 years, range 8'1-13-6) and required treatment until they were over 13 years; their mean age at final examination was 14-6 years (range 13-3-16-4) and mean AHt SDS was -0-6 (range -0.3 to -1-1). There were seven boys who were less than 8 years (F=0.01, p>0O1) . There was no difference between the mean AHt SDS for boys treated with cyclophosphamide (-0-79 (1.03), n=12) compared with those treated only with steroids (-0-10 (0-78) n=17), (F=2.67, p<0O1).
Puberty was assessed in all the subjects and a comparison was made with the expected age at the appearance of secondary sex characteristics.10 Nine boys were delayed (mean age 15-2 years, range 14*1-16-7) with pubic hair and genital stages at less than the third centile, and testicular volume was between 4 and 10 ml in seven. The three girls over the age of 12 years were progressing normally through puberty.
Demographic data and hormone profile analysis of the eight boys is given in table 3. All subjects slept throughout the study with normal electroencephalographic sleep patterns.1' Data of hormone profiles from a control group were lacking. Various studies over the last 15 years, however, have suggested a noticeable increase in pulsatility of growth hormone and gonadotrophins during the age range associated with normal puberty.1 Visual comparison with these documented hormone profiles suggested that six of the eight subjects had an abnormal blunting of their overnight profiles, with a decrease in pulse amplitude but not pulse number. A typical example of a blunted profile is shown (fig 4a) . Two of the boys not receiving steroids had higher concentration of hormones during the night as assessed visually and by pulse analysis (table 3) . One of the boys, the subject who had been off steroids for two years, had exceptionally high concentrations of growth hor- 
Discussion
We have shown that long term steroid treatment given through adolescence has an adverse effect on the rate of growth in boys with steroid sensitive nephrotic syndrome despite the use of a low dose alternate day regimen for the major part of the treatment course. We cannot say if this is also true for girls, who have a lower incidence of the syndrome and who, in our experience, require shorter treatment periods.
In boys, Ht SDS was significantly lower after several years of treatment, confirming data from previous studies.2 3 Other studies have found the effect on growth to be dose related.' 2 3 6 We were unable, in retrospect, to calculate accurately total steroid dose received by each child. If we make the assumption (although we have no statistical data) that the relapse rate reflects the total annual steroid dose, we can find no relation between this and growth retardation.
With increasing chronological age Ht SDS calculated at yearly intervals decreased (fig 3) . Obviously it is difficult to disentangle duration of treatment and total steroid dose from an age dependent effect group.bmj.com on July 11, 2017 -Published by http://adc.bmj.com/ Downloaded from as many of the peripubertal children will have been taking steroids for longer. The beginning of a fall in growth velocity at the age of 10 years, however, and its sudden and sharp decline in all the boys at the age of 13 years, combined with the high incidence of delayed appearance of secondary sex characteristics, is strong evidence in favour of an independent effect of steroids on the onset and progression of puberty and the pubertal growth spurt. The pubertal delay is unlikely to be due to the steroid sensitive nephrotic syndrome itself as the children remain free from disease as long as they are having steroid treatment. Furthermore, we have been unable to show a relation between the relapse rate (which we believe is a reflection of the severity of the syndrome) and the AHt SDS. In fact, over the age of 10 years the relapse rate is significantly less than before that age, whereas the major effect on growth was seen after 10 years.
We showed no relation between cyclophosphamide and growth problems. Foote et al found no effect of cyclophosphamide on In summary, we observed that boys with steroid sensitive nephrotic syndrome, who were treated with an alternate day steroid regimen for several years, do not maintain a normal rate of growth. As the growth delay occurs after the age of 10 years and is associated with delayed appearance of secondary sexual characteristics, we suggest that steroids interfere with the onset and progression of puberty and the pubertal growth spurt. Despite the evidence in the literature that final height is usually acceptable, this is a definite clinical problem with associated emotional difficulties. Overnight hormone profile analysis suggests that there is a disturbance of the hypothalamic-pituitary-gonadal axis with blunting of the expected overnight pulsatility of growth hormone and gonadotrophins. A disturbance of hypothalamic-pituitary function may be the major factor in the development of maturational delay and in severe cases this may be amenable to therapeutic agents such as luteinising hormone releasing hormone or anabolic steroids. 
